Donate

Industry News

Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved NovoSeven庐 RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size.

September 2, 2010

Novo Nordisk announced聽on August 10聽that the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation […]

Novo Nordisk provides a development update on two new investigational drugs for the bleeding disorders community.

August 30, 2010

The company’s ultra fastacting recombinant factor VIIa is progressing to a phase 3 trial after the successful completion of a phase 2 safety, pharmacokinetics and efficacy trial; the phase 3 trial is currently being designed.聽 A phase 3 trial for the factor XIII drug was recently been completed and showed that, compared to a historic […]

Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A

August 9, 2010

Pfizer Press Release Pfizer is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval for the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is an injectable recombinant factor VIII product previously approved by the FDA for both the […]

BioRx President Phil Rielly Wins Ernst & Young Entrepreneur of the Year庐 Award

July 28, 2010

(Cincinnati, Ohio)聽 July 20, 2010 – Philip Rielly, President and Co-founder of specialty pharmacy BioRx LLC, 聽has received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the Healthcare category in South 聽Central Ohio and Kentucky.聽 According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs 聽who are building and leading dynamic, […]

Winners announced for 2010 BioRx Educational Scholarships

July 21, 2010

News Release聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 June 21, 2010 (Cincinnati, Ohio)聽聽 BioRx, a specialty pharmacy, and Hemophilia of North Carolina, a non-profit organization that assists and educates persons affected by bleeding disorders, announce the winners of the 2010 BioRx Educational Scholarships.聽 Each of the winners receives a $2,000 scholarship.聽 The scholarships are funded by BioRx through an educational grant, […]

Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients

July 14, 2010

Buenos Aires, Argentina, (July 13, 2010) – Baxter International Inc. (NYSE: BAX) today announced final E.U./U.S. post-authorization safety surveillance (PASS) data that support the safety and efficacy profile of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] previously documented in prospective clinical trials in a new study published in the journal Hemophilia. see more…advate_pass

BioRX Announces New National Director of Operations

June 24, 2010

Randy Broyles, RPh has joined BioRx as National Director of Operations. See more…Randy Boyles

CSL Behring Launches 2 New Programs this month for Patients & Caregivers

April 27, 2010

1. FactorPlus: This is a new free product trial program for Helixate FS. Some of the highlights of the program: Shipment of trial product directly to聽patients homes (physician can choose where product should go to i.e. HTC or patients home) Inclusion of ancillary supplies with every shipment A welcome kit with helpful resources Improved availability […]

TODAY GRIFOLS INTRODUCES MIX2VIAL FILTER TRANSFER SETS

April 27, 2010

Los Angeles, California (April 23, 2010). Grifols USA, LLC (Grifols) today announced the availability of the Mix2Vial鈩 transer set for the reconstitution and administratioon of Grifols’ coagulation therapies. TheMix2Vial鈩⒙犅犅爄s a plastic, needle-free transfer device with a built-in 15 micron filter specifically designed to be used with the Sterile Water for Injection diluent packaged with Grifols […]

A Tribute to Dr. Robert Janco

March 10, 2010

Disease Area Lead, Pfizer Hematology Trusted colleague, outstanding clinician and friend of the hemophilia community, Dr. Robert “Bob” Janco passed away on March 9 after a short but aggressive illness. Bob had a wealth of experience in the diagnosis and clinical management of adults and children with congenital bleeding disorders.聽He most recently served at Disease […]

Infusion Set Needles [Manufactured by Nipro for Exelint]: Recall

January 26, 2010

Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets Exel/Exelint “Securetouch+” Safety Huber Infusion Sets Audience: Hospital Risk Managers, Surgical Service personnel FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint “Securetouch+” Safety Huber Infusion Sets, manufactured by Nipro Medical Corporation for Exelint International Corporation due to […]

340B Prime Vendor Program, managed by Apexus, and the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers.

January 14, 2010

IRVING, Texas/ Lansdale, Pa (January 14, 2010) – The 340B Prime Vendor Program, managed by Apexus, and聽 the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers in maximizing the benefits of 340B Drug Pricing Program and Prime Vendor Program discounts.聽 The two organizations are working together to […]

Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R …

January 13, 2010

Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R … FOXBusiness “Orphan drug exclusivity confirms Octapharma’s decision to focus exclusively on the treatment of von Willebrand patients. Wilate has a combination of two … Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R … 聽 聽 聽

Bayer is now accepting internship applications for the 2010 Bayer Hemophilia Leadership Development Program

December 22, 2009

The Bayer Hemophilia Leadership Development Program was developed with input from several members of the hemophilia community who saw a need for a program to develop future leaders in the bleeding disorders community. With their support, Bayer HealthCare Pharmaceuticals created an eight-week, paid summer internship at Bayer HealthCare’s U.S. Headquarters in Wayne, New Jersey. During […]

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Dis

December 8, 2009

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Disease 聽Milestone Marks Swiss Company’s Entrance into the U.S. Blood Coagulation Market HOBOKEN, N.J., Dec. 7 /PRNewswire/ — Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate® for the treatment of spontaneous and trauma-induced […]

The WFH receives the largest humanitarian aid donation in its history

December 1, 2009

NEWS RELEASE: 聽聽Donation represents more than 40 million international units to the WFH 聽(Montreal, December 2, 2009): As part of its continued commitment to hemophilia care around the world, Wyeth, now a part of Pfizer, has pledged more than 聽40 million international units (IUs) of factor concentrates to the World Federation of Hemophilia (WFH). This […]

1st Person with Hemophilia Reaches Mt. Rainier Summit to Raise Money for Inner-city Youth and International Bleeding Disorder Assistance Jeff Salantai

November 10, 2009

News Release Cincinnati, Ohio (November 9, 2009) 鈥 聽 On August 5, 2009, two BioRx employees, Jeff Salantai and Eric Hill, began hiking to the summit of Mt. Rainier.聽 They successfully reached the 14,410-foot summit on August 6.聽聽 Hill says, “We hoped to reach one of the largest peaks in the U.S., and we achieved […]

Wyeth Announces Recipients of the Soozie Courter “Sharing a Brighter Tomorrow” Hemophilia Scholarship Program

October 1, 2009

聽 Program Marks Continued Commitment to Education and Assistance to Hemophilia Community聽(Click Here for Announcement) 聽Collegeville, Pa., September 29, 2009 division of Wyeth (NYSE:WYE), today announced the recipients of the Soozie Courter “Sharing a Brighter Tomorrow” Hemophilia Scholarship Program for the 2009 assistance for higher education to individuals with hemophilia. Since 2002, Wyeth has donated […]

BioRx and Bayer Healthcare Offer Free

September 28, 2009

Cincinnati, Ohio (September 28, 2009) (Click Here for PDF)鈥 Bayer HealthCare and BioRx, a specialty pharmaceutical company, announce the availability of Quest for Infusion: Nate Goes to Camp, a new children’s book about hemophilia. 聽Quest for Infusion: Nate Goes to Camp, written by Chris Perretti Barnes and illustrated by Michael Graham, is the story of […]

PPTA LAUNCHES NEW WEBSITE TOOL

September 28, 2009

FOR IMMEDIATE RELEASE 聽September 23, 2009 聽Contact: Kara Flynn 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 Kym H. Kilbourne (443) 458-4669 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 (443) 458-4682 (443) 370-1177 (cellular) 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 (443) 995-2102 (cellular) kflynn@pptaglobal.org聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 kkilbourne@pptaglobal.org PPTA LAUNCHES NEW WEBSITE TOOL聽(Click Here for PDF) Enhancement to help potential plasma donors find plasma centers 聽ANNAPOLIS, MD (September 23, 2009) – Visitors to DonatingPlasma.org can more […]

Ablynx Initiates Phase II Clinical Trial for Alx-0081

September 3, 2009

聽 01 Sep 2009 Ablynx announced the initiation of a Phase II study for its anti-thrombotic Nanobody ALX-0081, a first-in-class Nanobody targeting von Willebrand Factor (vWF)GHENT, BELGIUM | September 1, 2009 | Ablynx [Euronext Brussels: ABLX] today announced the initiation of a Phase II study for its anti-thrombotic Nanobody ALX-0081, a first-in-class Nanobody targeting von […]

Ablynx Announces Positive Phase I Results for Subcutaneous Administration of it’s Ant-thrombotic NanobodyR (ALX-0681)

August 19, 2009

GHENT, Belgium, 18 August 2009 – Ablynx [Euronext Brussels: ABLX] today announced the positive results from its double-blind, randomized, placebo-controlled, single and multiple dose Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor (vWF). The positive Phase I data support the progression of ALX-0681 towards […]

Bayer HealthCare Launches Hemophilia Self-Infusion Training Program

July 28, 2009

News Release聽聽 Innovative BayCuff鈩 Program Empowers Young Members of Hemophilia A Community to Take Control of Their Treatment WAYNE, NJ, July 9, 2009 – Today, Bayer HealthCare Pharmaceuticals launched the BayCuff鈩 self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their […]

Google News Alert for: von Willibrand

July 20, 2009

Google News Alert for: von Willibrand Bio/Data Corporation Launches vW Select(TM) – The World’s First … SYS-CON Media – Montvale,NJ,USA vW Select is the first and only complete assay that measures the functional activity of the von Willebrand Factor. A deficiency of von Willebrand Factor …

Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug

July 20, 2009

Tuesday, June 30, 2009, 11:36am EDT Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug Philadelphia Business Journal Wyeth Pharmaceuticals said Tuesday that it has formed an exclusive worldwide collaboration with Catalyst Biosciences Inc. to develop treatments for hemophilia and other bleeding conditions. Collegeville, Pa.-based Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) said it will pay South […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.